Medical Xpress
JANUARY 5, 2023
National Institutes of Health researchers have published an assessment of 13 studies that took a genotype-first approach to patient care. This approach contrasts with the typical phenotype-first approach to clinical research, which starts with clinical findings.
Worldwide Clinical Trials
FEBRUARY 6, 2023
The best course of action will depend on many variables, such as the disease or population being studied and the genotype/phenotype relationship, risk, and impact on care. The post To Share or Not to Share Failed Genetic Screening Results with Patients appeared first on Worldwide Clinical Trials. Read the full article!
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
OCTOBER 4, 2022
BioIVT has acquired Fidelis Research, an 85-site clinical biospecimen collection network in Southeastern Europe. . Fidelis Research also possesses cell isolation capabilities and provides custom contract research services for pharmaceutical companies and clinical research organisations (CROs). .
pharmaphorum
JANUARY 18, 2023
Pharmaceutical companies and biotechs are also adapting their approaches, launching patient finding and engagement programmes that can start years before clinical trials begin and allow them to run ‘recontact by genotype’ studies that the Resilience Project would have liked to do. Giving participants something in return.
pharmaphorum
JANUARY 21, 2022
The findings have been submitted to the Genotype-to-Phenotype National Virology Consortium (G2P-UK), the New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG) and the Joint Committee on Vaccination and Immunisation (JCVI). Overall, antibody levels were nearly 2.5
The Pharma Data
NOVEMBER 10, 2020
The assay is being explored for applications in clinical research, including new drug trials, based on its capability to identify patients with Alzheimer’s disease and also to predict their risk of progression. The trial also found APOE genotyping helpful for predicting ATN (amyloid, tau, neurodegeneration) classification.
XTalks
APRIL 24, 2023
“Rare disease clinical trials are complex due to the additional scientific, medical, operational and regulatory requirements of newly emerging advanced therapies, such as gene therapy,” says Dr. Terence Eagleton, MB BS, Senior Medical Director at the global clinical research organization (CRO) Medpace.
Expert insights. Personalized for you.
75 
Let's personalize your content